Leucid Bio
Caroline Malai Hull has a strong background in scientific research and leadership roles. Caroline Malai began their career as a PhD student at King's College London in 2011, where they focused on their research as a Postdoctoral Research Associate until 2021. During their time at King's College London, Caroline also held the position of Consultant at LEUCID BIO from 2018 to 2020. Caroline Malai then advanced to the role of Senior Scientist at LEUCID BIO from 2020 to 2021. Following this, Caroline served as Team Lead at LEUCID BIO from 2021 to 2022. Currently, they hold the position of Associate Director at LEUCID BIO starting from July 2022. Caroline's work experience spans over a decade and demonstrates their expertise in scientific research and leadership in the biotechnology industry.
Caroline Malai Hull completed their education in a sequential manner. From 2011 to 2015, they pursued a Doctor of Philosophy (PhD) degree in Immunology at King's College London. Prior to that, from 2010 to 2011, they attended Imperial College London, although no specific degree or field of study is mentioned during this time.
This person is not in any teams
Leucid Bio
1 followers
Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part ofLeucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts.